clinical trial · NCT04209686
Paclitaxel, Pembrolizumab and Olaparib in Previously Treated Advanced Gastric Adenocarcinoma
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins·phase2·active not recruiting·n = 36
Advanced Gastric AdenocarcinomaPaclitaxelOlaparibPembrolizumab
brief summary
The purpose of this study is to evaluate the safety and clinical activity of paclitaxel plus olaparib and pembrolizumab in patients with previously treated advanced Gastric Cancer (GC).
started
Jul 31, 2020
primary completion
Sep 1, 2028
completion
Sep 1, 2028
last updated
Dec 3, 2025
official title
Phase 2 Study of Paclitaxel, Pembrolizumab and Olaparib in Previously Treated Advanced Gastric Adenocarcinoma
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol